Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) Director Kurt M. Eichler purchased 1,996 shares of the business’s stock in a transaction that occurred on Monday, September 19th. The stock was bought at an average price of $12.50 per share, with a total value of $24,950.00. Following the completion of the purchase, the director now owns 429,644 shares of the company’s stock, valued at approximately $5,370,550. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Shares of Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) opened at 11.80 on Wednesday. Spring Bank Pharmaceuticals Inc has a 52 week low of $7.62 and a 52 week high of $13.25. The company has a 50 day moving average price of $11.64 and a 200 day moving average price of $10.62. The company’s market capitalization is $91.53 million.

Separately, William Blair began coverage on Spring Bank Pharmaceuticals in a research note on Friday, August 19th. They issued an “outperform” rating and a $26.00 price target for the company.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/kurt-m-eichler-acquires-1996-shares-of-spring-bank-pharmaceuticals-inc-sbph-stock.html

About Spring Bank Pharmaceuticals

Spring Bank Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of therapeutics using its small molecule nucleic acid hybrid (SMNH), chemistry platform. Its SMNH compounds are small segments of nucleic acids that the Company designs to selectively target and modulate the activity of specific proteins implicated in various disease states.

5 Day Chart for NASDAQ:SBPH

Receive News & Ratings for Spring Bank Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.